2007 Sustainability Report - Baxter Sustainability Report

More documents

Recommendations

Info

Access to HealthcareSustainability PriorityBaxter willstrengthen accessto healthcarethrough productdonations, strategicsponsorshipsand productdevelopmentSee page 5 for a summary ofBaxter's sustainability prioritiesMany medical breakthroughs have improved the lives of people with serious medicalconditions. Without access to these therapies, however, patients cannot realize thesebenefits. This is a particular problem in developing countries, where poor infrastructure,political instability, poverty, lack of education, restrictive regulatory frameworks, andinadequate availability and affordability of medical products are among the factors thatcan limit access. Addressing these issues requires cooperation among governments,non-governmental organizations, corporations, medical professionals and others. Baxter’sapproach to improving access to healthcare reflects the complexity of these issues.PRODUCT DONATIONS AND GRANTSIn 2007, Baxter donated more than $31 million in products to help people in 53 countries(see map). Beginning in 2007, Baxter included patient assistance program donations in itsoverall product donation totals to align with comprehensive reporting and benchmarkingdata. Also in 2007, The Baxter International Foundation made grants totaling $3.1 millionto 68 organizations in 18 countries, largely to improve the quality and accessibility ofhealthcare for the disadvantaged and underserved in communities where Baxter employeeslive and work.Baxter’s Community Relations team manages the donations process, guided by Baxter’sGlobal Product Donation Policy, which covers such areas as regulatory requirements,licensing, expiration and dating, accounting and tax laws, and export requirements. Theteam works with supply chain managers and others in the company to match availableinventory to current need. Baxter works with two primary relief organizations: AmeriCares,an international disaster-relief and humanitarian-aid organization that airlifts criticalshipments to areas suffering from natural disasters or political strife; and Direct ReliefInternational, a non-profit, non-sectarian humanitarian-assistance organization focused onproviding medical assistance to people victimized by poverty, disaster and civil unrest.In 2007, Baxter donations included intravenous (IV) solutions and other products to theJabe Hospital and Rohero Emergency Clinic in Burundi, which serves more than 1,300outpatients each month in one of the poorest communities in the capital city of Bujumbura;the St. Francis of Assisi Clinic in Managua, Nicaragua, a small urban clinic that treats about100 patients a day; the only pediatric hospital in El Salvador to help fight dengue fever; andto support refugees from the Darfur region of Sudan.Grants from The Baxter International Foundation support an array of programs. In 2007,these included speech therapy for children, physical rehabilitation services, mental healthservices for low-income youth, clinical services for women who are homeless or victimsof domestic violence, and improved access to healthcare for children, the uninsured andthe elderly.32BAXTER 2007 sustainability report | community support
STRATEGIC SPONSORSHIPSBaxter also seeks to increase healthcare access by targeting sponsorship opportunitiesacross its business units, functions and regions. For example, Baxter’s BioScience businessis the founding sponsor of the Global Alliance for Progress (GAP) in hemophilia, a programlaunched by the World Federation of Hemophilia to improve diagnosis and treatmentin developing countries. Since the project launched in 2003, 41,395 new patients withbleeding disorders have been diagnosed globally, including 31,189 with hemophilia.PRODUCT DevelopmentBaxter recognizes that innovation has a critical role to play in increasing access tohealthcare for those at the "base of the pyramid" in developing and emerging economies.The company plans to increase its R&D investments in this area. For example, in manydeveloping countries, people with end-stage renal disease, or kidney failure, currently gountreated. Baxter is the world’s leading provider of products for peritoneal dialysis (PD), aself-administered therapy that, unlike hemodialysis (HD), does not require an infrastructureof hospitals or clinics. Baxter's PD products and services offer potential cost benefits aswell as an improved quality of life for many patients.above In Romania, two-year-old Roxannareceived a Baxter anti-coagulantmedication through AmeriCares, oneof Baxter’s humanitarian-aid anddisaster-relief partners, enabling her tosurvive a life-saving surgical procedure.Photo courtesy of AmeriCares.Baxter plans to launch a new automated peritoneal dialysis (APD) machine particularlysuited to the infrastructure limitations of developing markets. The technology will beintroduced initially in India and will include features tailored to local needs, such as a powersource that accommodates electrical power fluctuations that may occur in less developedareas. APD administers therapy overnight, enabling patients to work during the day, whichcan make the therapy more affordable. See more information in the full report online.Baxter technology also is playing a role in pandemic preparedness. The company’s verocelltechnology can produce influenza vaccine more quickly than traditional productionmethods, enabling the company to rapidly produce large quantities of vaccine in the eventof a pandemic. See more information in the full report online.Overview of Baxter globalCommunity support in 2007Product Donations 1Cash Contributions 2Product and Cash Contributions1Includes value of product donations calculatedusing a combination of average wholesale priceand average sales price. See “Baxter and TheBaxter International Foundation CharitableGiving” table on page 31 for detail.2Includes contributions from Baxter and The BaxterInternational Foundation.33 sustainability.baxter.com/community_support
Page 1 and 2: 2007SustainabilityReportsustainabil
Page 3 and 4: Company ProfileMore online:sustaina
Page 5 and 6: “When you’re in abusiness like
Page 7 and 8: BAXTER SUSTAINABILITY PRIORITIES AN
Page 10 and 11: 8BAXTER 2007 sustainability report
Page 12 and 13: Talent ManagementTo ensure the sust
Page 14 and 15: Global InclusionSustainability Prio
Page 18 and 19: EHS 2007 Year in ReviewENVIRONMENTA
Page 20 and 21: EHS AuditsDuring an EHS audit, audi
Page 22 and 23: ProductResponsibility20BAXTER 2007
Page 24 and 25: Quality and SafetyBaxter's reputati
Page 26 and 27: Q&A with norbert riedel R&D at Baxt
Page 30 and 31: Supplier DiversityBaxter tries to d
Page 36 and 37: ight Baxter employees Kathy Wang an
Page 38 and 39: Economic ImpactsMore online:sustain
Page 40 and 41: Public PolicyMore online:sustainabi
Page 42 and 43: Summary Data TablePlease see releva
Page 44: Baxter International Inc.One Baxter

2007 Sustainability Report - Baxter Sustainability Report

Create successful ePaper yourself

Delete template?

Save as template?